

Index

A

- ABHD5, 113
- ALT, 239
- Angiogenesis, hepatitis C virus promotion, 126
- Animal models, hepatitis C virus
 - importance, 37–38
 - mice
 - genetically humanized mice, 40–42
 - human live chimeric mice, 39–40
 - transgenic mice, 39
 - primates, 38–39
 - prospects, 46–47
 - surrogate models
 - George–Baker virus B, 42–43
 - nonprimate or equine hepacivirus, 43
 - overview, 42
 - rodent hepacivirus
 - mouse, 43–45
 - rat, 45–46
- Antibody response. *See* Humoral immunity, hepatitis C virus
- ANXA2, 109
- AP2M1, 109
- ApoA, 111
- ApoC1, 73
- ApoE, 111–114
- Assembly, hepatitis C virus
 - core protein association with cytoplasmic lipid droplets, 107–108
 - overview, 106
 - prospects for study, 114
 - RNA synthesis, membrane niche, 106–107
 - stages
 - envelopment of virus particles, 109–110
 - lipid droplet trafficking, 108–109
 - virus particle density heterogeneity, 106

B

- B cell. *See* Humoral immunity, hepatitis C virus
- B-cell lymphoma, direct-acting antiviral therapy, 249–250
- β -Catenin, hepatitis C virus induction, 126–127
- Blood bank, hepatitis C virus testing, 3–4
- Broadly neutralizing antibody. *See* Humoral immunity, hepatitis C virus

C

- Cardiovascular disease
 - direct-acting antiviral therapy, 250
 - hepatitis C virus induction, 242
- CBL, virus entry role, 70
- CD36, 19
- CD81
 - genetically humanized mice, 40–41
 - structure, 16–18
 - virus entry role, 53–55, 66, 69–70, 73, 193
- CDHRH2, 199
- CDHRH3, 200
- Cell culture, hepatitis C virus
 - clone isolation, 28
 - infectious virus production
 - chimeric constructs, 32–33
 - overview, 31
 - JFH-1 strain culture, 29
 - JFH-2 strain culture, 30
 - overview, 25–27
 - permissive cell lines, 33
 - subgenomic replicon assembly, 28–29
- Cirrhosis, liver
 - direct-acting antiviral therapy
 - compensated cirrhosis patient treatment, 211–212
 - decompensating cirrhosis patient treatment, 212, 243–245
 - hepatitis C virus induction mechanisms, 122–128
- CLDN1, virus entry role, 40–41, 55, 66–70
- Cognitive impairment
 - direct-acting antiviral therapy, 250–251
 - hepatitis C virus induction, 242–243
- Cryoglobulinemia
 - direct-acting antiviral therapy, 249
 - hepatitis C virus induction, 242
- CypA, 96

D

- DAAs. *See* Direct-acting antivirals
- DC-SIGN, 56
- DDX3X, 97
- Depression, hepatitis C virus induction, 242–243
- Diabetes
 - direct-acting antiviral therapy, 250
 - hepatitis C virus induction, 242

Index

- Direct-acting antivirals (DAAs)
approved drug types and combinations, 211
cirrhosis-free patient treatment, 211–212
compensated cirrhosis patient treatment, 211–212
decompensating cirrhosis patient treatment, 212, 243–245
extrahepatic manifestation management, 219
goals of therapy, 210
hepatocellular carcinoma patient treatment, 212, 219, 245–249
historical perspective, 227–228
indications, 211
limitations, 228–230
liver transplantation patient treatment, 219
morbidity and mortality impact, 231–232
natural killer cell role in therapy, 161
overview, 209–210
policy on use
failures and successes, 230–231
Global Health Sector Strategy on Viral Hepatitis, 230
Sustainable Development Goals, 230
pretreatment assessment
classical assessment, 210–211
simplified assessment, 212
prospects, 233–234
recommendations
AASL/IDSA, 216–218
EASL, 213–215
retreatment, 219
subpopulation studies, 232–233
transmission impact, 232
- Discovery, hepatitis C virus, 1–3
- E**
- E1
antigenic properties, 194–197
E2 dimerization, 16, 72
functions, 16
structure, 15–16
virus entry role, 72–74
- E2
antigenic properties, 194–197
E1 dimerization, 16, 72
functions, 16
neutralizing face, genetic variability, and structural flexibility, 197–198
structure, 16
virus entry role, 72–74
- EGFR
hepatitis C virus up-regulation, 124–126
virus entry role, 68
- Egress, hepatitis C virus
apolipoprotein association following egress, 113–114
overview, 106
prospects for study, 114
stages
egress into endoplasmic reticulum lumen, 110–113
secretion from endoplasmic reticulum lumen, 113
- EHMs. *See* Extrahepatic manifestations
- Entry, hepatitis C virus
host factors
attachment factors, 56, 66
entry cofactors, 68–69
entry factors, 66–68
overview, 55–56
table of factors, 57–65
membrane fusion, 71–74
overview of control, 53–55
prospects for study, 74–75
protein–protein interactions, 69–70
- Epidemiology, hepatitis C virus
blood transfusion, 226–227
closed setting inhabitants, 225–226
human immunodeficiency virus patients, 225
injected drug abusers, 224–225
overview, 37–38, 223–224, 237
- ERAPI*, 239
- EWI2, virus entry role, 70
- Extrahepatic manifestations (EHMs).
See also specific manifestations
cardiovascular disease, 242
chronic immune stimulation in induction, 241–242
diabetes, 242
direct-acting antiviral management, 219
direct-acting antiviral therapy, 249–252
neurological disorders, 242–243
overview, 240–241
- F**
- Fatigue, hepatitis C virus induction, 242–243
- Fibrosis, hepatitis C virus induction mechanisms in liver, 122–127
- G**
- GBV-B. *See* George–Baker virus B
- George–Baker virus B (GBV-B), animal models, 42–43
- GHSS. *See* Global Health Sector Strategy on Viral Hepatitis
- Global Health Sector Strategy on Viral Hepatitis (GHSS), 230, 260, 266
- Glutathione peroxidase, 122
- GSK, 127

- H**
- HCC. *See* Hepatocellular carcinoma
- Hedgehog, hepatitis C virus–induced fibrogenesis role, 124, 129
- Hepatitis C
- acute disease, 238–239
 - chronic disease, 239–240
- Hepatocellular carcinoma (HCC)
- direct-acting antiviral therapy, 212, 219, 245–249
 - hepatitis C virus induction, 128–129
 - natural history, 239
 - overview, 121
- HIV. *See* Human immunodeficiency virus
- HMG-CoA reductase, 97
- HNRNPk, 109
- Human immunodeficiency virus (HIV), hepatitis C virus coinfection, 225
- Humoral immunity, hepatitis C virus
- autoantibodies and rheumatoid factor, 192–194
 - overview, 189–191
 - prospects for study, 200
 - rational vaccine design from neutralizing antibody epitopes
 - antigenic properties of E1 and E2, 194–197
 - broadly neutralizing antibody immunogenetics, 198–200
 - E2 neutralizing face, genetic variability, and structural flexibility, 197–198 - overview, 194
 - serological versus neutralizing antibody responses, 191–192
 - vaccine response, 284–285
- I**
- IL-1. *See* Interleukin 1
- IL-6. *See* Interleukin 6
- IL-15. *See* Interleukin 15
- Inflammation, hepatitis C virus induction
- mechanisms, 122–127, 145–148
- Innate immunity, hepatitis C virus
- evasion, 141–142
 - inflammation, 145–148
 - interferons
 - antiviral activity, 141–143
 - hepatitis C virus infection response, 142
 - interferon γ
 - genetics in hepatitis C virus infection, 143–145
 - overview of response, 142–143 - interleukin 1 cross talk, 147–148
 - therapy prospects, 149
 - types I and III interferon responses, 142–143 - overview in liver, 139–140, 156
 - prospects for study, 148–149
 - RIG-1-like receptors
 - overview, 139–140
 - pathway, 140–141
- Insulin resistance
- direct-acting antiviral therapy, 250
 - hepatitis C virus induction, 242
- Interferon
- antiviral activity, 141–143
 - hepatitis C virus infection response, 142
 - interferon γ
 - genetics in hepatitis C virus infection, 143–145
 - overview of response, 142–143, 157, 159 - interleukin 1 cross talk, 147–148
 - therapy for hepatitis C virus
 - historical perspective, 227
 - prospects, 149, 160–161 - types I and III interferon responses to hepatitis C virus, 142–143
- Interleukin 1 (IL-1), hepatitis C virus response, 146–148
- Interleukin 6 (IL-6), hepatitis C virus induction of STAT3 signaling, 125
- Interleukin 15 (IL-15), 158
- Internal ribosome entry site (IRES), hepatitis C virus protein synthesis regulation, 83
- IRES. *See* Internal ribosome entry site
- ITBG1, virus entry role, 69
- K**
- KAK2, 129
- L**
- LIMP-2, 19
- Liver transplantation, direct-acting antiviral therapy, 219
- L-SIGN, 56
- LY6E, 72
- M**
- Macrophage
- hepatitis C virus response, 161–163
 - natural killer cell cross talk, 163–164
- MAPK, hepatitis C virus up-regulation of signaling, 125–126
- MERTK, 240
- Metabolism, hepatitis C virus alteration in liver, 127–128
- miR-122, 95–96
- N**
- NAFLD. *See* Nonalcoholic fatty liver disease
- NANBH. *See* Non-A, non-B hepatitis

Index

- Natural killer (NK) cell
 direct-acting antiviral therapy role, 161
 hepatitis C virus response, 157–160
 interferon therapy role, 160–161
 liver cells, 160
 macrophage cross talk, 163–164
 overview, 156–157
 receptors, 157
- NK cell. *See* Natural killer cell
- NKG2A, 161, 163
- NKG2D, 163
- NLRP3, 146
- Non-A, non-B hepatitis (NANBH), historical perspective, 1–3
- Nonalcoholic fatty liver disease (NAFLD), hepatitis C virus pathogenesis similarities, 130
- Nonprimate or equine hepacivirus (NPHV), animal models, 43
- NPC1, 91
- NPC1L1, virus entry role, 68
- NPC2, 91
- NPHV. *See* Nonprimate or equine hepacivirus
- Nrf2, 122
- NS2, 84, 87
- NS3, 84, 94, 108
- NS4A, 94, 107
- NS4B, 87, 89, 107
- NS5A, 5, 87, 89–90, 94–97, 107–109
- NS5B, 93–94
- O**
- OCLN, virus entry role, 55, 66–70
- OSBP, 91
- P**
- PD-1, 179
- PDGF, 124
- PI4KA, 90, 96
- PI4P, 90–91
- PLA2G16, 72
- PLA2G4A, 108
- Policy
 direct-acting antiviral use
 failures and successes, 230–231
 Global Health Sector Strategy on Viral Hepatitis, 230
 Sustainable Development Goals, 230
 elimination of hepatitis C virus
 feasibility assessment
 burden of disease, 264
 costs, 264
 elimination versus control, 265–266
 epidemiologic susceptibility, 261
 intervention availability, 261–262
 overview, 260
 political commitment, 263, 265
 shown feasibility of elimination, 262–263
 synergy between elimination efforts and other interventions, 265
 Global Health Sector Strategy on Viral Hepatitis, 260
 prospects, 271
 strategies
 delivering for equity, 269–270
 financing, 270
 information for focused action, 267
 innovation for acceleration, 270–271
 interventions for impact, 267–269
 overview, 266–267
- R**
- Rap2b, virus entry role, 69–70
- Replication, hepatitis C virus genome replication factors
 CypA, 96
 lipid-modulating host cell factors, 97
 miR-122, 95–96
 NS3, 94
 NS4A, 94
 NS5A, 94–97
 NS5B, 93–94
 RNA elements, 91–93
 XRN1, 95
 XRN2, 95
 membrane changes, 87–89
 overview, 83–87
 prospects for study, 97–98
 replication organelle
 factors in formation
 host factors, 89–91
 virus factors, 89
 history of study, 87–90
- RF. *See* Rheumatoid factor
- Rheumatoid factor (RF), hepatitis C virus induction, 193–194
- RHV. *See* Rodent hepacivirus
- RNF7, 240
- Rodent hepacivirus (RHV), animal models
 mouse, 43–45
 rat, 45–46
- S**
- SCARB1. *See* SR-B1
- SDGs. *See* Sustainable Development Goals
- SMADs, 124
- SR-B1
 structure, 17, 19
 virus entry role, 40–41, 55, 66–69

- SR-B1. *See* SCARB1
SREBP, 97
SRFBP1, virus entry role, 68
Structure, hepatitis C virus
 CD81, 16–18
 core, 14
 E1, 15–16
 E2, 16
 overview, 11–13
 prospects for study, 20–21
 SR-B1, 17, 19
 virion, 13–14
Sustainable Development Goals (SDGs), 230
- T**
- T cell
 acute hepatitis C response, 238
 failure in chronic hepatitis C virus infection
 CD4⁺ T cells, 177–178
 CD8⁺ T cells, 178–179
 prospects for study, 179–181
 hepatitis C virus clearance
 acute versus persisting infection response,
 173–177
 reinfection protection, 174–175
 sustained T-cell response, 172
 vaccine-primed T cells, 175
 overview of types, 171–172
 vaccine response
 clinical trial design, 281–282
 overview, 279, 281
 replication-defective vectors, 283–284
TFRC, virus entry role, 68, 70
TGF- β . *See* Transforming growth factor β
Transforming growth factor β (TGF- β), hepatitis C
 virus modulation, 124–125, 159
TRC40, 14
TULPI, 240
- V**
- Vaccination, hepatitis C virus
 challenges
 genetic diversity of virus, 279
 overview, 277–278
 testing of vaccine, 279–280
 economic incentives, 278–279
 historical perspective, 5–7
 immune response
 evidence for protective immunity, 280
 humoral immunity, 284–285
 T-cell response
 clinical trial design, 281–282
 overview, 279, 281
 replication-defective vectors,
 283–284
 populations to benefit, 285–286
 rational vaccine design from neutralizing antibody
 epitopes
 antigenic properties of E1 and E2,
 194–197
 broadly neutralizing antibody immunogenetics,
 198–200
 E2 neutralizing face, genetic variability, and
 structural flexibility, 197–198
 overview, 194
 traditional vaccine design approaches, 279
VEGE, hepatitis C virus up-regulation, 126
VP1, 19
VP2, 19
- W**
- Wnt, hepatitis C virus activation, 126–127
- X**
- XRN1, 95
XRN2, 95